Skip to main content
Caplight Logo









PersonGen BioTherapeutics

PersonGen BioTherapeutics

Private
SuzhouHealthcare & Life Scienceshttps://persongen.com/

Last Round

Series B

Jan 1, 2022

Total Funding Raised

$51.6M

Company Overview

PersonGen BioTherapeutics is a biotechnology company that develops innovative cellular immunotherapies, including CAR-T cell therapies, for the treatment of cancer and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

cellular immunotherapyCAR-T therapyallogeneic cell therapyoff-the-shelf CAR-Tcell therapy platformin-vivo cell engineeringuniversal CAR-TCD7-targeted therapyhematological malignanciessolid tumor treatmentnext-gen immunotherapyGMP manufacturingexosome preparationautoimmune disease therapybiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PersonGen BioTherapeutics Comparables

Compare PersonGen BioTherapeutics with similar companies based on industry and business-model similarity.

PersonGen BioTherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Hebei Senlang Biotechnology Co., Ltd.
88%
Wuhan Bio-Raid Biotechnology
87%
Juventas Cell Therapy Ltd.
86%

PersonGen BioTherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 1, 2022
Series AMay 1, 2021
StrategicNov 11, 2015
AngelAug 1, 2012

PersonGen BioTherapeutics Investors

Notable investors and investment history

PersonGen BioTherapeutics investors
InvestorRounds
Shenzhen Sangel Venture CapitalSeries A
YuanBio Venture CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 4, 2025

    Monthly visitors grew 2789% MoM to 1.3K.

  • Jan 1, 2022

    $31M round led by Nanjing Huatai Guoxin and China Kim Kaide.

PersonGen BioTherapeutics Filings

Explore SEC and related filing metadata, where available.

PersonGen BioTherapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about PersonGen BioTherapeutics's valuation, stock price, and market status.

Is PersonGen BioTherapeutics a public or private company?

PersonGen BioTherapeutics is a private company.

What is the current stock price of PersonGen BioTherapeutics?

PersonGen BioTherapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is PersonGen BioTherapeutics worth (valuation)?

Valuation information for PersonGen BioTherapeutics is not publicly available.

Can I buy PersonGen BioTherapeutics stock?

PersonGen BioTherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was PersonGen BioTherapeutics's last funding round?

PersonGen BioTherapeutics's most recent funding round was Series B on January 1, 2022.

Who are the main investors in PersonGen BioTherapeutics?

Key investors in PersonGen BioTherapeutics include YuanBio Venture Capital.

Will PersonGen BioTherapeutics IPO soon?

No public IPO plans have been announced for PersonGen BioTherapeutics.

How can I track PersonGen BioTherapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor PersonGen BioTherapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSuzhou
Year Founded2010
Last FundingJan 1, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?